ABSTRACT
Background@#Nail psoriasis is a common clinically significant symptom of psoriasis. However, few studies have focused on the characteristics and course of toenail psoriasis. @*Objective@#To investigate the treatment response of toenail psoriasis during a 52-week period of ustekinumab use. @*Methods@#Patients were evaluated using the Nail Psoriasis Severity Index (NAPSI) at every injection visit. NAPSI score changes throughout the treatment were analyzed. The treatment response in each toenail and each NAPSI characteristic was also analyzed. @*Results@#A total of 22 patients with chronic plaque psoriasis with concomitant toenail psoriasis were examined. Several characteristics such as ridging or onychomycosis that mimic psoriasis or hinder the evaluation were identified. NAPSI significantly improved during the treatment (p＜0.05). The big and second toes were significantly improved after 52 weeks of ustekinumab treatment (p＜0.05). Pitting and oil-drop discoloration were the only two characteristics that showed significant changes post-treatment (p＜0.05). @*Conclusion@#Ustekinumab proved to be efficacious in treating toenail psoriasis.Because of the factors that hinder the NAPSI scoring, only NAPSI scores of the first and second toes can be used.
ABSTRACT
BACKGROUND: Scalp psoriasis severely affects patients' quality of life, and patients may occasionally be refractory to topical steroid application. Although systemic therapy combined with topical steroid application is recommended for treatment-resistant scalp psoriasis, previous research has not reported whether such combination treatment improves patients' quality of life.OBJECTIVE: This study investigated whether combination therapy using oral cyclosporine and topical steroid reduces the severity of scalp psoriasis and improves patients' quality of life compared with the use of topical steroid alone.METHODS: The study included 23 patients with scalp psoriasis who were categorized as patients who received topical steroid therapy alone vs. those who received combination therapy with topical steroid and oral cyclosporine for 12 weeks. The severity of psoriasis and quality of life were evaluated at 4, 8, and 12 weeks of treatment.RESULTS: No significant improvement was observed in the severity of psoriasis or in patients' quality of life during the treatment period in patients receiving topical steroid alone. Patients treated with a combination of topical steroid and oral cyclosporine showed a reduction in the severity of psoriasis from the 4th week of treatment and their quality of life improved from the 12th week of treatment.CONCLUSION: Combination therapy with oral cyclosporine and topical steroid may reduce the severity of scalp psoriasis and improve patients' quality of life.
Subject(s)
Humans , Cyclosporine , Psoriasis , Quality of Life , ScalpABSTRACT
BACKGROUND: No study to date has focused on the changes in laboratory test results and related risk factors in patients with psoriasis treated with prolonged Cyclosporine A (CsA) therapy. OBJECTIVE: The objective of this study was to investigate the changes of laboratory values and related risk factors in patients with psoriasis treated with CsA in a real-world setting. METHODS: Records of patients with psoriasis treated with CsA at an outpatient clinic were collected, and a Cox proportional hazards regression model was used. RESULTS: Of the 128 patients included in this study, 28 patients (21.9%) showed laboratory test abnormalities over a mean medication period of 11.6 months. Older age (hazard ratio [HR], 1.174; 95% confidence interval [CI], 1.068~1.370; p=0.007) and pre-existing kidney disease (HR, 0.008; 95% CI, 0~0.205; p=0.001) significantly increased the risk of renal dysfunction. Male sex was the only significant risk factor for liver enzyme elevation (HR, 0.284; 95% CI, 0.081~0.784; p=0.026) and uric acid abnormality (HR, 0.048; 95% CI, 0~0.372; p=0.046). CONCLUSION: This is an in-depth analysis of laboratory changes and related risk factors in patients with psoriasis treated with CsA. Liver is the most commonly affected organ of CsA toxicity. Older age, male sex, and presence of kidney disease were risk factors associated with laboratory abnormality during CsA treatment.
Subject(s)
Humans , Male , Ambulatory Care Facilities , Clinical Laboratory Techniques , Cyclosporine , Kidney Diseases , Liver , Psoriasis , Risk Factors , Uric AcidABSTRACT
BACKGROUND: Drug survival, defined as the time until discontinuation, is a parameter reflecting real-world therapeutic effectiveness. Few studies have examined the influence of economic factors on the drug survival of biologic agents for psoriasis, particularly in Asian countries. OBJECTIVE: To determine the drug survival for ustekinumab in real-life settings and investigate the factors affecting drug survival for psoriasis patients in Korea. METHODS: We evaluated 98 psoriasis patients who were treated with ustekinumab at a single center. We analyzed the efficacy and drug survival of ustekinumab. Cox proportional hazard analysis and competing risk regression analysis were performed to reveal the factors affecting the drug survival of ustekinumab. RESULTS: The overall mean drug survival was 1,596 days (95% confidence interval [CI], 904~2,288). Among the 39 cessations of ustekinumab treatment, 9 (23.1%) patients discontinued treatment after experiencing satisfactory results. Multivariate Cox proportional hazard analysis revealed that paying on patients' own expense was the major predictor for the discontinuation of ustekinumab (hazard ratio [HR], 9.696; 95% CI, 4.088~22.998). Competing risk regression analysis modeling of discontinuation because of factors other than satisfaction of an event also revealed that ustekinumab treatment at the patient's expense (HR, 4.138; 95% CI, 1.684~10.168) was a predictor of discontinuation rather than satisfaction. CONCLUSION: The results of our study revealed that the cost of biologics treatment affects the drug survival of ustekinumab and suggested that economic factors affect the drug survival of ustekinumab treatment in Korea.